CL vs MDLZ

Colgate-Palmolive (CL) trades at a slight discount to sector peers on P/E (21.86 vs 22.17) but faces meaningful headwinds from near-zero revenue growth (1.9% YoY) and deteriorating short-term momentum, with 1Y and 6M returns of -12.6% and -13.4%, respectively. The company maintains elite profitability—Gross Margin of 60.15%, Operating Margin of 20.23%, and ROE of 293.63%—supported by consistent earnings beats over the last 25 quarters, though recent Q/Q EPS growth has turned negative. Elevated leverage (Debt/Equity: 6.80) and weak liquidity (Current Ratio: 0.93) raise structural concerns, while the 2.66% dividend yield offers modest income appeal with a sustainable 57% payout ratio. Analysts are constructive with a $87.26 target implying ~12% upside, but lack of insider activity and stagnant top-line expansion cap near-term catalysts.

MDLZ presents a conflicted profile with a stable Piotroski F-Score of 4/9 but severe valuation gaps, trading at $57.42 against a Graham Number of $29.28 and an Intrinsic Value of $13.23. While revenue growth remains robust at 9.3%, the company is facing a critical earnings collapse (-60.4% YoY) and an unsustainable dividend payout ratio of 102.65%. The strong analyst 'buy' consensus and consistent earnings beat history are offset by poor liquidity ratios and a bearish technical trend.